Combining AI-driven analysis of pathology slide images with clinical data and expanded genomic profiles offers superior accuracy in predicting breast cancer recurrence compared to the standard 21-gene recurrence score alone. This multimodal approach represents the future of risk assessment.
In HR+/HER2- early breast cancer, registry data shows only the MammaPrint High-2 (ultra-high risk) subgroup derives significant benefit from adding anthracycline-based chemotherapy. This NCCN-adopted finding allows for therapy de-escalation in MammaPrint High-1 patients, sparing them unnecessary toxicity.
HER2+/ER+ breast cancer is not a single disease. Genomic subtyping reveals distinct biological profiles (luminal A/B, HER2-enriched) with pathologic complete response rates to therapy ranging from just 26% to as high as 61%, signaling the need for tailored treatment strategies.
Counterintuitively, in premenopausal women on ovarian suppression, the more potent endocrine therapy (Aromatase Inhibitor) provided the most benefit over Tamoxifen in BCI-Low tumors. These tumors are less ER-driven, suggesting other pathways make them vulnerable to maximal estrogen deprivation.
A prospective registry trial demonstrated the real-world clinical utility of the BCI test. Its results directly changed physicians' recommendations for or against extended endocrine therapy in 41% of cases, while also increasing patient confidence in the shared treatment decision.
The SET index, which measures estrogen receptor activity, identified a subset of patients in the NSABP B42 trial who derived a massive 17% absolute improvement in 10-year breast cancer-free interval from extended letrozole. This contrasts sharply with the modest 3% benefit seen in the overall trial population.